Evidence map›Paper›PMID 32708049›Full record

ReviewCancers2020

Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors.

María Rosario Chica-Parrado, Ana Godoy-Ortiz, Begoña Jiménez, Nuria Ribelles, Isabel Barragan, Emilio Alba

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06438055 (Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06438055 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results

TypeinterventionalSponsorTianjin Medical University Cancer Institute and HospitalRan2024 to 2026Enrolled40ConditionsRefractory Breast CancerArmsChemotherapy and targeted-therapy guided by organoid drug sensitivity test
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. A predictive model for neoadjuvant therapy response in breast cancer.Metabolomics : Official journal of the Metabolomic Society · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

María Rosario Chica-ParradoInstitute of Biomedical Research in Malaga (IBIMA), Regional and Virgen de la Victoria University Hospitals Campus de Teatinos s/n, 29010 Málaga, Spain.
Ana Godoy-OrtizInstitute of Biomedical Research in Malaga (IBIMA), Regional and Virgen de la Victoria University Hospitals Campus de Teatinos s/n, 29010 Málaga, Spain.
Begoña JiménezInstitute of Biomedical Research in Malaga (IBIMA), Regional and Virgen de la Victoria University Hospitals Campus de Teatinos s/n, 29010 Málaga, Spain.
Nuria RibellesInstitute of Biomedical Research in Malaga (IBIMA), Regional and Virgen de la Victoria University Hospitals Campus de Teatinos s/n, 29010 Málaga, Spain.
Isabel BarraganInstitute of Biomedical Research in Malaga (IBIMA), Regional and Virgen de la Victoria University Hospitals Campus de Teatinos s/n, 29010 Málaga, Spain.
Emilio AlbaInstitute of Biomedical Research in Malaga (IBIMA), Regional and Virgen de la Victoria University Hospitals Campus de Teatinos s/n, 29010 Málaga, Spain.
Instituto de Investigación Biomédica de Málaga · ESKarolinska Institutet · SE

Funding

Consejería de Salud, Junta de Andalucía SA0263/2017Instituto de Salud Carlos III PI15/01823Seventh Framework Programme 799818
6 · The paper itself

Abstract

Neoadjuvant Chemotherapy (NAC) in Breast Cancer (BC) has proved useful for the reduction in tumor burden prior to surgery, allowing for a more extensive breast preservation and the eradication of subjacent micrometastases. However, the impact on prognosis is highly dependent on the establishment of Pathological Complete Response (pCR), in particular for Triple Negative (TN) and Hormonal Receptor negative/Human Epidermal growth factor Receptor 2 positive (HR-/HER2+) subtypes. Several pCR predictors, such as PAM50, Integrative Cluster (IntClust), mutations in PI3KCA, or the Trastuzumab Risk model (TRAR), are useful molecular tools for estimating response to treatment and are prognostic. Major evolution events during BC NAC that feature the Residual Disease (RD) are the loss of HR and HER2, which are prognostic of bad outcome, and stemness and immune depletion-related gene expression aberrations. This dynamic nature of the determinants of response to BC NAC, together with the extensive heterogeneity of BC, raises the need to discern the individual and subtype-specific determinants of resistance. Moreover, refining the current approaches for a comprehensive monitoring of tumor evolution during treatment, RD, and eventual recurrences is essential for identifying new actionable alterations and the integral best management of the disease.

Indexed as

breast cancerneoadjuvant chemotherapypathological complete responsepredictive markersresidual disease

Identifiers

PMID32708049
PMCPMC7463925
OpenAlexW3044225655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.